

WYETH CONTRACT REMINDER FOR NEUMEGA®

Oncology Associates would like to remind you of its contract for Neumega®. The agreement provides valuable savings for the product Neumega® in 5 mg vials and 5 mg vials in 7/box quantities.



Neumega® is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are high risk of severe thrombocytopenia. Please contact your local Wyeth representative or call OA at **888-732-7352** for more information.

IN OTHER NEWS...

NEW COMPENDIA LISTING FOR MANTLE CELL LYMPHOMA (MCL)



On June 24, 2005, Thomson MICROMEDEX published an "accepted" compendium listing for bortezomib as a second-line treatment of MCL in the USP DI®

SUMMARY

Preclinical Studies

Preclinical studies of bortezomib have been conducted using mantle cell lymphoma (MCL) cell lines and MCL primary patient cells. Bortezomib has shown *in vitro* activity as a single agent and synergistic activity in combination with doxorubicin, vincristine, cyclophosphamide, cytarabine, and mitoxantrone.

Phase I Trials

Phase I trials have been conducted to determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of bortezomib in patients with hematologic malignancies including MCL. There was preliminary evidence of anti-tumor activity of bortezomib as monotherapy and in combination with fludarabine.

Phase II Trials

In a phase II trial of bortezomib in patients with relapsed or refractory indolent or aggressive non-Hodgkin's lymphoma (NHL), of 29 assessable patients with MCL there were 6 patients with complete response (CR) and 6 patients with partial response (PR) for an overall response rate of 41%.

In a II trial of bortezomib in 74 patients with relapsed indolent NHL and MCL, the overall response rate in 37 evaluable patients with MCL was 40% [3 CR, 2 Cru (unconfirmed CR), and 10 PR].

In a phase II trial of bortezomib in relapsed/refractory NHL and Hodgkin lymphoma (HL), the overall response rate (CR+PR) in 24 patients with MCL was 29%. *In vitro* sensitivity to bortezomib of lymph node biopsy samples or peripheral blood specimens correlated with clinical response.

In a phase II trial of bortezomib in MCL, there were 1 CRu and 12 PR in 28 evaluable patients (response rate = 46%); 8 of these responses occurred in 2 cycles, while the remaining 5 responses occurred in 4 cycles.

In another phase II trial of bortezomib in MCL (PINNACLE), the overall response rate in 48 patients was 42%, with 8% CR+CRu. Median duration of response (DOR) was 6.2 months, and median time to progression (TTP) was 4.3 months at the current stage 2 efficacy analysis. Median survival has not been reached at a median follow-up of 10.5 months.

Data from phase I and phase II trials indicate that bortezomib has anti-tumor activity in patients with MCL as a single agent and as part of combination chemotherapy.

Bortezomib appears to be tolerable with manageable toxicities in patients with MCL; toxicities were generally similar across trials. The most common toxicities included thrombocytopenia, sensory and/or motor neuropathy, fatigue, GI toxicities (particularly diarrhea), pain (neuropathic and myalgia), and anemia.

For more information, call **1-866-VELCADE** or visit www.velcade.com.

NEW COMPENDIA LISTING FOR ZOMETA INJECTION



Effective August 10, 2005, the United States Pharmacopeia Drug Information (USPDI) listed ZOMETA

(zoledronic acid) Injection in its compendium for the treatment of drug-induced osteopenia, secondary to androgen-deprivation therapy in prostate cancer patients (prophylaxis). ZOMETA was approved by the FDA for hypercalcemia of malignancy in August 2001 and it was subsequently approved in February 2002 for multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard cancer therapy.

To view the full USPDI monograph for ZOMETA, visit <http://uspdi.micromedex.com/> and select Zoledronic Acid under the revised August monographs.